Last reviewed · How we verify

NCT07000851: I-CAN

Imaging Studies in Corticobasal Syndrome

Recruiting now Last updated 7 July 2025
What this trial tests

trial testing C-11 ER176 Radiotracer in Cortico Basal Degeneration in 80 participants. Currently enrolling.

Timeline
25 June 2025
Primary endpoint
30 March 2030
30 March 2031

Quick facts

Lead sponsorJennifer Whitwell
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment80
Start date25 June 2025
Primary completion30 March 2030
Estimated completion30 March 2031
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Jennifer Whitwell

Who can join

18 and older, any sex, with Cortico Basal Degeneration or Corticobasal Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary goal of this study is to investigate inflammation and white matter damage in corticobasal syndrome and determine whether these processes are related to each other. The investigator's will address our goal by using neuroimaging and blood plasma biomarkers, as well as molecular pathology.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Cortico Basal Degeneration

Currently open trials in the same condition.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07000851.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing